Trimeris and its partner Roche are considering an alternative means of delivery for their HIV drug Fuzeon after a recent study indicated it can be administered effectively without a needle.

“Based on the data from this study, Roche and Trimeris are exploring plans to further evaluate use of Fuzeon with this needle-free injection system,” the companies said in a joint statement after the test results were announced last week.

The study found that “equivalent drug levels” of Fuzeon were found in patients’ blood after they received it through a needle-free injection device known as Biojector 2000.

One of the primary objections against Fuzeon is its required needle administration.

The study involved 27 patients who received Fuzeon for the first time.

The Biojector 2000 system is manufactured by Bioject Medical technologies. It uses a Co2-powered injector.